Article Text

Download PDFPDF
Concurrent interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies
  1. B. Y. Karlan,
  2. T. Chamorro,
  3. J. M. Fowler,
  4. L. I. Muderspach,
  5. L. D. Lagasse and
  6. S. Greenberg*
  1. * Divisions of Gynecologic Oncology and Therapeutic Radiology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, USA
  1. Address for correspondence: Beth Y. Karlan, M.D., Department of Obstetrics and Gynecology, Rm 1738, Cedars-Sinai Medical Center, 8700 Beverly Blvd. Los Angeles, CA 90048, USA.

Abstract

Patients with unresectable locally recurrent gynecologic malignancies pose a difficult therapeutic challenge. Conventional therapies are frequently unsuccessful and offer only marginal palliation. In this study, interstitial 192iridium-needle implants and concomitant infusional 5-fluorouracil (5FU) and cisplatin (CDDP) or carboplatin (CBDCA) chemotherapy were used to treat 14 women with recurrent pelvic tumors. Malignancies of the cervix, endometrium ovary, tube and vulva are represented; all patients were heavily pretreated. Twenty interstitial implants were performed in these 14 patients. Needle distributions and doses were individualized to accommodate the recurrent tumor volumes. Tumor responses were seen in 12 patients (six complete and six partial responses). Four women remain clinically free of disease and four are alive with disease at 18–34 months of follow-up. There were no severe acute toxicities, however, four patients have subsequently developed fistulae associated with tumor progression. Although longer follow-up is required, the high response rate, wide applicability and acceptable toxicity observed in this heavily pretreated patient population warrant further study of combined interstitial radiation and chemotherapy.

  • concomitant chemotherapy
  • interstitial radiation
  • pelvic recurrence.

Statistics from Altmetric.com

Footnotes

  • Supported in part by a Career Development Award to Dr Karlan from the American Cancer Society. Dr Muderspach is an American Cancer Society clinical fellow.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.